Clinical trialNCT05554367Active, not recruitingPhase 2Interventional

Palbociclib and Binimetinib in RAS-Mutant Cancers, A ComboMATCH Treatment Trial

SponsorNational Cancer Institute (NCI)Enrollment199Exocrine Pancreas CarcinomaMalignant Solid NeoplasmOvarian Low Grade Serous AdenocarcinomaStage IV Ovarian Cancer AJCC v8Stage IV Pancreatic Cancer AJCC v8

View the registry record on ClinicalTrials.gov

Summary

The lay summary the sponsor registered on ClinicalTrials.gov.

This phase II ComboMATCH treatment trial evaluates the effectiveness of palbociclib and binimetinib in treating patients with RAS-mutated cancers. Palbociclib and binimetinib are both in a class of medications called kinase inhibitors. They work by blocking the action of abnormal proteins that signals cancer cells to multiply. This trial may help researchers understand if giving the combination of palbociclib and binimetinib can help improve the amount of time before the cancer grows in patients with patients with low grade serous ovarian cancer who have certain changes in the tumor DNA. This trial may also help researchers understand if giving the combination of palbociclib and binimetinib can help improve outcomes among patients with low grade serous ovarian cancer who have previously received a MEK inhibitor. For patients with other tumors, with the exception of lung cancer, colon cancer, melanoma and low grade serous ovarian cancers, this trial may help researchers understand if giving the combination of palbociclib and binimetinib can improve the clinical outcome of survival without progression in patients who have certain changes in their tumor's DNA.

clinicaltrials.gov ↗

Investigators

The overall officials registered on this study. Names that resolve to a findmyKOL profile link to it; the rest are shown as registered.

Geoffrey I Shapiro
Alliance for Clinical Trials in Oncology
Principal InvestigatorKOL profile →
clinicaltrials.gov ↗

A profile link is shown only when the registered name resolves to a person record with a confident, namesake-checked match; ambiguous names stay unlinked.

Sites

265 registered facilities, with the per-site recruitment status where the registry publishes one. ClinicalTrials.gov does not publish per-site enrollment counts.

Puerto Rico

Centro Comprensivo de Cancer de Upr
San Juan, Puerto Rico

United States

University of Alabama at Birmingham Cancer Center
Birmingham, Alabama, United States
University of South Alabama Mitchell Cancer Institute
Mobile, Alabama, United States
Providence Alaska Medical Center
Anchorage, Alaska, United States
Uc San Diego Health System - Encinitas
Encinitas, California, United States
Uc San Diego Moores Cancer Center
La Jolla, California, United States
Va Palo Alto Health Care System
Palo Alto, California, United States
Uc San Diego Medical Center - Hillcrest
San Diego, California, United States
Uchealth University of Colorado Hospital
Aurora, Colorado, United States
Cancer Care and Hematology-Fort Collins
Fort Collins, Colorado, United States
Poudre Valley Hospital
Fort Collins, Colorado, United States
Uchealth Greeley Hospital
Greeley, Colorado, United States
Medical Center of the Rockies
Loveland, Colorado, United States
Um Sylvester Comprehensive Cancer Center at Aventura
Aventura, Florida, United States
Um Sylvester Comprehensive Cancer Center at Coral Gables
Coral Gables, Florida, United States
Um Sylvester Comprehensive Cancer Center at Deerfield Beach
Deerfield Beach, Florida, United States
Uf Health Cancer Institute - Gainesville
Gainesville, Florida, United States
Um Sylvester Comprehensive Cancer Center at Kendall
Miami, Florida, United States
University of Miami Miller School of Medicine-Sylvester Cancer Center
Miami, Florida, United States
Um Sylvester Comprehensive Cancer Center at Plantation
Plantation, Florida, United States
Saint Alphonsus Cancer Care Center-Boise
Boise, Idaho, United States
Saint Luke'S Cancer Institute - Boise
Boise, Idaho, United States
Saint Alphonsus Cancer Care Center-Caldwell
Caldwell, Idaho, United States
Kootenai Health - Coeur D'Alene
Coeur d'Alene, Idaho, United States
Saint Luke'S Cancer Institute - Fruitland
Fruitland, Idaho, United States
Saint Luke'S Cancer Institute - Meridian
Meridian, Idaho, United States
Saint Alphonsus Cancer Care Center-Nampa
Nampa, Idaho, United States
Saint Luke'S Cancer Institute - Nampa
Nampa, Idaho, United States
Kootenai Clinic Cancer Services - Post Falls
Post Falls, Idaho, United States
Kootenai Clinic Cancer Services - Sandpoint
Sandpoint, Idaho, United States
Advocate Good Shepherd Hospital
Barrington, Illinois, United States
Illinois Cancercare-Bloomington
Bloomington, Illinois, United States
Illinois Cancercare-Canton
Canton, Illinois, United States
Illinois Cancercare-Carthage
Carthage, Illinois, United States
Advocate Illinois Masonic Medical Center
Chicago, Illinois, United States
John H Stroger Jr Hospital of Cook County
Chicago, Illinois, United States
Northwestern University
Chicago, Illinois, United States
University of Chicago Comprehensive Cancer Center
Chicago, Illinois, United States
Amg Crystal Lake - Oncology
Crystal Lake, Illinois, United States
Carle at the Riverfront
Danville, Illinois, United States

225 more sites on the registry record.ClinicalTrials.gov ↗

Site investigator names are published by ClinicalTrials.gov only while a study recruits, so completed studies list sites without them.

Drugs studied

The drug and biological interventions registered on this study, normalized to their RxNorm ingredient where possible.

Binimetinib →Palbociclib →

Linked drugs open the directory filtered to KOLs working with them.clinicaltrials.gov ↗

Registration & key dates

Registry attributes as recorded on the ClinicalTrials.gov study record.

Start: 13 Dec 2023
Primary completion: 26 Aug 2028
Completion: 26 Aug 2028
Last update posted: 21 Aug 2026
Registered enrollment: 199
Registry id: NCT05554367

clinicaltrials.gov ↗

Source: ClinicalTrials.gov, via the CTTI AACT database, data as of 24 Aug 2026. Registry facts are shown as registered by the study sponsor; findmyKOL does not interpret them.